RU96105946A - METHOD FOR SENSITIZING CANCER CELLS TO A LYSIS MEDIATED BY KILLER CELLS - Google Patents

METHOD FOR SENSITIZING CANCER CELLS TO A LYSIS MEDIATED BY KILLER CELLS

Info

Publication number
RU96105946A
RU96105946A RU96105946/14A RU96105946A RU96105946A RU 96105946 A RU96105946 A RU 96105946A RU 96105946/14 A RU96105946/14 A RU 96105946/14A RU 96105946 A RU96105946 A RU 96105946A RU 96105946 A RU96105946 A RU 96105946A
Authority
RU
Russia
Prior art keywords
antiestrogen
killer cells
triphenylethylene
cells
killer
Prior art date
Application number
RU96105946/14A
Other languages
Russian (ru)
Other versions
RU2153332C2 (en
Inventor
Бэрал Эдвард
Берци Иштван
Нейджи Ева
Кангас Лаури
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed filed Critical
Publication of RU96105946A publication Critical patent/RU96105946A/en
Application granted granted Critical
Publication of RU2153332C2 publication Critical patent/RU2153332C2/en

Links

Claims (11)

1. Способ сенсибилизации раковых клеток к лизису, опосредованному клетками-киллерами, который включает в себя введение пациенту, нуждающемуся в таком воздействии, эффективного количества антиэстрогена и клеток-киллеров совместно или последовательно, причем клетки-киллеры выбирают из группы ЕКК, ЛАКК и ЦТЛ, а антиэстроген выбирают из группы трифенилэтиленовых антиэстрогенов.1. A method of sensitizing cancer cells to lysis mediated by killer cells, which includes administering to a patient in need of such an effect, an effective amount of antiestrogen and killer cells together or sequentially, the killer cells being selected from the group of NKK, LACK and CTL, and the antiestrogen is selected from the group of triphenylethylene antiestrogens. 2. Способ по п. 1, отличающийся тем, что трифенилэтиленовым антиэстрогеном является тамоксифен или торемифен или их фармацевтически приемлемые соли. 2. The method according to p. 1, characterized in that the triphenylethylene antiestrogen is tamoxifen or toremifene or their pharmaceutically acceptable salts. 3. Способ по п. 2, отличающийся тем, что тамоксифен или его фармацевтически приемлемую соль вводят перорально в дневной дозе 20-40 мг. 3. The method according to p. 2, characterized in that tamoxifen or its pharmaceutically acceptable salt is administered orally in a daily dose of 20-40 mg. 4. Способ по п. 2, отличающийся тем, что торемифен или его фармацевтически приемлемую соль вводят перорально в дневной дозе 40-240 мг. 4. The method according to p. 2, characterized in that toremifene or its pharmaceutically acceptable salt is administered orally in a daily dose of 40-240 mg. 5. Способ сенсибилизации раковых клеток к лизису, опосредованному клетками-киллерами, который включает в себя индуцирование образования клеток-киллеров в организме пациента с помощью одного из известных иммуностимулирующих методов в течение первого периода лечения и затем введение эффективного количества трифенилэтиленового антиэстрогена в течение второго периода лечения. 5. A method for sensitizing cancer cells to killer cell-mediated lysis, which comprises inducing the formation of killer cells in a patient using one of the known immunostimulating methods during the first treatment period and then administering an effective amount of triphenylethylene antiestrogen during the second treatment period . 6. Способ по п. 5, отличающийся тем, что трифенилэтиленовым антиэстрогеном является тамоксифен или торемифен или их фармацевтически приемлемые соли. 6. The method according to p. 5, characterized in that the triphenylethylene antiestrogen is tamoxifen or toremifene or their pharmaceutically acceptable salts. 7. Способ по п. 5 или 6, отличающийся тем, что иммуностимулирование осуществляется посредством введения интерлейкина-2. 7. The method according to p. 5 or 6, characterized in that the immunostimulation is carried out by the introduction of interleukin-2. 8. Применение антиэстрогена класса трифенилэтилена в производстве лекарственного средства для сенсибилизации раковых клеток к лизису, опосредованному клетками-киллерами. 8. The use of triphenylethylene class antiestrogen in the manufacture of a medicament for sensitizing cancer cells to lysis mediated by killer cells. 9. Применение по п. 8, отличающееся тем, что его сочетают с клетками-киллерами, выбранными из группы ЕКК, ЛАКК и ЦТЛ. 9. The use according to claim 8, characterized in that it is combined with killer cells selected from the EKK, LACK and CTL groups. 10. Применение по п. 8, отличающееся тем, что его сочетают с иммуностимулирующим агентом, таким, как интерлейкин-2. 10. The use according to claim 8, characterized in that it is combined with an immunostimulating agent, such as interleukin-2. 11. Антиэстроген класса трифенилэтилена для применения в совместном системном введении с клетками-киллерами с целью сенсибилизации раковых клеток к лизису, опосредованному клетками-киллерами. 11. An antiestrogen of the triphenylethylene class for use in joint systemic administration with killer cells in order to sensitize cancer cells to lysis mediated by killer cells.
RU96105946/14A 1993-08-09 1994-08-02 Method of sensitization of cancer cells to lysis mediated by killer-cells RU2153332C2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US10351993A 1993-08-09 1993-08-09
US08/103,519 1993-08-09

Publications (2)

Publication Number Publication Date
RU96105946A true RU96105946A (en) 1998-09-27
RU2153332C2 RU2153332C2 (en) 2000-07-27

Family

ID=22295643

Family Applications (1)

Application Number Title Priority Date Filing Date
RU96105946/14A RU2153332C2 (en) 1993-08-09 1994-08-02 Method of sensitization of cancer cells to lysis mediated by killer-cells

Country Status (16)

Country Link
US (1) US5788964A (en)
EP (1) EP0726772B1 (en)
JP (1) JPH09501174A (en)
KR (1) KR100340091B1 (en)
AT (1) ATE208207T1 (en)
AU (1) AU693459B2 (en)
CA (1) CA2168584C (en)
CZ (1) CZ285508B6 (en)
DE (1) DE69429011T2 (en)
ES (1) ES2167373T3 (en)
HU (1) HUT74425A (en)
NO (1) NO316823B1 (en)
NZ (1) NZ269149A (en)
RU (1) RU2153332C2 (en)
SK (1) SK283124B6 (en)
WO (1) WO1995004544A1 (en)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2686899B1 (en) * 1992-01-31 1995-09-01 Rhone Poulenc Rorer Sa NOVEL BIOLOGICALLY ACTIVE POLYPEPTIDES, THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM.
HU223344B1 (en) * 1997-08-13 2004-06-28 Máté Hidvégi Immunostimulant and metastasis-inhibiting fermented dried material, pharmaceutical compositions containing same, process for its production and its uses
US6413533B1 (en) 1998-05-07 2002-07-02 The University Of Tennessee Research Corporation Method for chemoprevention of prostate cancer
US20030130316A1 (en) * 2000-03-20 2003-07-10 Steiner Mitchell S. Method for chemoprevention of prostate cancer
US20040092602A1 (en) * 1998-05-07 2004-05-13 Steiner Mitchell S. Method for treatment and chemoprevention of prostate cancer
US20040176470A1 (en) * 1998-05-07 2004-09-09 Steiner Mitchell S. Method for treatment and chemoprevention of prostate cancer
US6632447B1 (en) 1998-05-07 2003-10-14 The University Of Tennessee Research Corporation Method for chemoprevention of prostate cancer
ATE283043T1 (en) 1998-05-07 2004-12-15 Univ Tennessee Res Corp MEDICATION FOR THE TREATMENT OF INTRAEPITHELIAL PROSTATE NEOPLASIA
US6410043B1 (en) 1998-05-07 2002-06-25 The University Of Tennessee Research Corporation Method for chemoprevention of prostate cancer
EP1372717A2 (en) * 2001-03-23 2004-01-02 Aphton Corporation Combination treatment of pancreatic cancer
US20090191232A1 (en) * 2001-05-04 2009-07-30 Gevas Philip C Combination therapy for the treatment of tumors
EP1401477A4 (en) * 2001-05-25 2005-02-02 Human Genome Sciences Chemokine beta-1 fusion proteins
CA2450898A1 (en) * 2001-07-09 2003-01-23 Aphton Corporation Treatment and prevention of cancerous and pre-cancerous conditions of the liver, lung and esophagus
US20080249183A1 (en) * 2001-11-29 2008-10-09 Steiner Mitchell S Treatment of androgen-deprivation induced osteoporosis
US6555095B1 (en) 2001-12-14 2003-04-29 Avon Products, Inc. Topical compositions and methods of application
ES2500918T3 (en) 2001-12-21 2014-10-01 Human Genome Sciences, Inc. Albumin and interferon beta fusion proteins
WO2004088326A2 (en) * 2003-03-28 2004-10-14 Aphton Corporation Gastrin hormone immunoassays
ES2426916T3 (en) * 2003-08-01 2013-10-25 A & G Pharmaceutical, Inc. Compositions and procedures to restore sensitivity to treatment with HER2 antagonists
EP1730193A2 (en) * 2004-03-29 2006-12-13 Receptor Biologix, Inc. Monoclonal antibodies to gastrin hormone
CN101048659B (en) * 2004-09-22 2013-03-13 受体生物技术公司 Monoclonal antibodies to progastrin
US20060270641A1 (en) * 2005-05-31 2006-11-30 Steiner Mitchell S Method for chemoprevention of prostate cancer
AU2011211699B2 (en) * 2010-02-04 2015-01-22 Toray Industries, Inc. Pharmaceutical composition for treating and/or preventing cancer
KR20120093002A (en) * 2011-02-14 2012-08-22 (주)에이티젠 Method for diagnosing cancer and diagnosis kit using measurement of nk cell activity
WO2016106146A1 (en) 2014-12-23 2016-06-30 The Regents Of The University Of California Methods for immunomodulation of cancer and infectious disease therapy
KR20200015943A (en) 2017-06-15 2020-02-13 캔설 어드밴스 아이엔씨 Compositions and Methods for Inducing Humoral and Cellular Immunity to Tumors and Cancers

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5024833A (en) * 1988-03-10 1991-06-18 Industrial Farmaceutica Serono Spa Combined interferon/antiestrogen therapy for treatment of breast cancer
US5057423A (en) * 1987-12-18 1991-10-15 University Of Pittsburgh Method for the preparation of pure LAK-active lymphocytes
US5189212A (en) * 1990-09-07 1993-02-23 University Of Georgia Research Foundation, Inc. Triarylethylene carboxylic acids with estrogenic activity
CA2109426A1 (en) * 1991-04-30 1992-10-31 Hiroyuki Kouji Triphenylethylene derivative and pharmaceutical drug containing the same

Similar Documents

Publication Publication Date Title
RU96105946A (en) METHOD FOR SENSITIZING CANCER CELLS TO A LYSIS MEDIATED BY KILLER CELLS
JP2848556B2 (en) Cough / cold combination drug containing non-steroidal anti-inflammatory drug
JPH06509099A (en) Compositions and methods for transdermal delivery of diclofenac
ES2830447T3 (en) Method for the prevention and / or treatment of cognitive impairment associated with aging and neuroinflammation
RU96122884A (en) HUMAN CANCER TREATMENT METHOD
KR960703616A (en) Sensitization of Cancer Cells for Killer Cell Intercalation
RU2007138582A (en) ORAL DOSAGE FORMS OF HEMCITABINE DERIVATIVES
PT2033635E (en) Use of phenylbutyric acid or salts thereof for treating pruritus
RU95101385A (en) Products containing g-csf and tnf-binding protein
JP2011506505A (en) Medicament and its production method and use in the treatment of painful neuropathy
ES2698363T3 (en) Compositions of oxprenolol to treat cancer
KR900017577A (en) How to raise cell-mediated immunity using polyamine derivatives
US9750714B2 (en) Pharmaceutical use of 3, 4-bis-benzylsulfonylbutyronitrile
JP2008143856A (en) Pharmaceutical compounded with nonsteroidal anti-inflammatory agent
JP2611003B2 (en) Immunostimulants
JP2021506907A5 (en)
US9149488B2 (en) Pharmaceutical composition and use of diethyl (2-cyanoethyl)phosphonate
JPH08268884A (en) Use of 7-substituted-2-aminotetralin for preparing medicinalcomposition being useful for therapy of septic shock and antipyretic and antiphlogistic medicinal composition
EA200300430A1 (en) NEW PHARMACEUTICAL COMPOSITIONS CONTAINING EPINASTINES AND PSEVDOEDFEDRIN
BRPI0902144A2 (en) process for preparing a solid oral administration pharmaceutical composition containing the active ingredients glycosamine and meloxicam and use of the association between glycosamine and meloxicam
RU2019180C1 (en) Remedy for treatment of hypodermic fibrosarcoma and method of its preparation
CN1166320A (en) Composite of zinc containing compound and glutamines
EP3110412B1 (en) 4-benzylsulfonyl-2-butenenitrile
RU2021118773A (en) COMPOUNDS SUITABLE FOR HIV THERAPY
JP2015189758A (en) external pharmaceutical composition